Articles tagged with Chemotherapy
SWOG Cancer Research Network will share results of their work in 30 presentations at the 2024 American Society of Clinical Oncology Annual Meeting, May 31 – June 4 in Chicago. The research focuses on improving cancer treatments and reducing devastating side effects.
A new study published in Nature Biomedical Engineering shows that targeted cancer treatment using antibody-displaying extracellular vesicles reduces tumour growth and improves survival in mice. The treatment has the potential to be used against other diseases and cancer types, offering a more effective and fewer side effects compared t...
Researchers found no significant 'participation effect' in cancer trials, contrary to common belief among patients and healthcare providers. The study's results provide reassurance that not enrolling in a trial doesn't disadvantage a patient's survival outcomes.
A Phase III randomized, placebo-controlled trial found that donepezil did not improve memory or other cognitive functions in breast cancer survivors. Despite this, researchers emphasize the need for further trials with different approaches to address cancer-related cognitive impairment.
Researchers found that blocking PI3K-beta makes glioblastoma cells more sensitive to temozolomide treatment, slowing down tumor growth. The study's findings could lead to new treatments for patients with chemotherapy-resistant glioblastoma.
Researchers found a new pathway to cancer cell death led by the Schlafen11 (SLFN11) gene. This discovery could have implications for cancer treatment and patient outcomes.
Researchers discuss therapeutic opportunities for hypermutated urothelial carcinomas that are resistant to immunotherapy, including the potential of targeted therapies. High TMB is associated with defects in mismatch repair proteins and can lead to increased sensitivity to cancer treatments.
A UCLA-led study reveals that chemotherapy for early-stage breast cancer in women over 65 can lead to a significant decline in physical function. The study found that 30% of older women who received chemotherapy experienced a substantial decline, with climbing stairs and walking being the most affected activities.
Researchers found that SARS-CoV-2 spike protein interrupts p53-MDM2 interaction but does not bind with p53 protein in cancer cells. The study also shows that SARS-CoV-2 spike suppresses p53-dependent gene activation, leading to increased cell viability after chemotherapy exposure.
MIT engineers have developed a closed-loop drug-delivery system that can improve chemotherapy outcomes by continuously monitoring patients and adjusting dosage. The new system, called CLAUDIA, uses commercially available equipment to analyze blood samples every five minutes and adjust infusion rates in real-time.
A new study published in JNCI Cancer Spectrum found that following a healthy diet, such as the DASH diet, lowers the risk of cardiovascular disease in breast cancer survivors. Women whose diets were most similar to DASH had a 47% lower risk of heart failure and other cardiovascular-related events.
A study by the University of Gothenburg found that women with triple-negative breast cancer and high immune cell levels have a lower relapse risk after surgery. This suggests that these patients may not need chemotherapy, despite having faster-growing tumors and higher relapse rates than other breast cancers.
Scientists at CNIC have identified mechanisms by which anthracyclines damage the hearts of cancer patients, leading to cardiac injury. The study suggests that a protein-enriched diet may prevent muscle atrophy caused by anthracycline chemotherapy.
Researchers have developed a new treatment that uses tailored doses of anti-cancer drugs released directly into the surgical cavity to treat liver cancer. The approach has shown promise in reducing recurrence rates and minimizing chemotherapy side effects, with potential applications for other types of cancer.
Researchers discovered MIA-602's effectiveness against Doxorubicin-resistant acute myeloid leukemia (AML), demonstrating reduced cell viability and tumor volume. The study suggests MIA-602 as a potential alternative treatment approach for AML, potentially circumventing chemotherapy side effects.
Researchers developed a nanosized polymer that selectively delivers chemotherapeutic drugs to blood vessels supporting tumor growth. The treatment eliminates colorectal cancer liver metastases and prolongs mice survival after a single dose-therapy.
A pilot study by UCLA Health investigators suggests that treating patients with immunotherapy and chemotherapy before surgery may improve long-term outcomes for those with borderline resectable pancreatic cancer. The study found a higher rate of successful tumor removal and increased overall survival when compared to historical controls.
Researchers developed an AI model to detect viable tumor cells in osteosarcoma patients, improving prognosis predictions. The model showed comparable detection performance to pathologists and reduced inter-assessor variability, enabling timely assessment.
A new study suggests that early-stage triple-negative breast cancer (TNBC) patients with high levels of immune cells in their tumors may have a lower risk of recurrence and better survival rates even without chemotherapy. Higher TILs in breast cancer tissue were associated with lower recurrence rates among participants.
Researchers from the University of Southern Denmark have identified specific groups of cells driving resistance to chemotherapy in TNBC, offering new biomarkers and alternative treatment options. The studies shed light on the mechanisms behind chemoresistance and its epigenetic control.
The study found that neoadjuvant chemotherapy increased median overall survival to 37 months and progression-free survival to 26 months. 57.2% of patients showed an objective response, with nearly one-fourth experiencing lymph-node pathologic complete response.
A nationwide study finds that individuals diagnosed with colon cancer who resided in previously redlined neighborhoods are more likely to be diagnosed with advanced-stage disease and have worse survival rates. The research highlights the long-lasting impact of institutional racism on access to quality cancer care.
Researchers at the University of Toronto have found that two enzymes, APOBEC3C and APOBEC3D, promote resistance to chemotherapy drug gemcitabine in pancreatic cancer cells. Removing these enzymes can kill cancer cells by stymieing DNA repair.
Researchers assessed the feasibility of dual PD-L1/CTLA-4 checkpoint inhibition in Stage II or III hormone receptor-positive, HER2-negative breast cancer. Eight patients received upfront durvalumab and tremelimumab prior to neoadjuvant chemotherapy, showing mixed responses and limited benefit.
Researchers have identified a protein, NPEPPS, that enables cisplatin-resistant cancer cells to become responsive to treatment. This discovery could increase patient eligibility and make platinum-based therapies more effective.
The University of Cincinnati Cancer Center team has opened a Phase 2 clinical trial to test a new combination treatment for glioblastomas, a deadly form of brain tumors. The treatment uses letrozole, a drug that targets an enzyme present in breast cancer cells, and temozolomide, a chemotherapy drug already approved as a GBM treatment.
A team of scientists discovered new fusion sites in protein evolution that enable faster and more targeted drug development. By combining evolutionary processes with synthetic biology, they created customized biological drugs with improved therapeutic properties.
A new study suggests that tailored treatment can predict the response of breast cancer patients to chemotherapy, allowing for safe omission of extensive lymph node removal. The MARI protocol showed a 95% overall survival rate and 89% disease-free survival rate in patients who achieved pathological complete response.
The ALEXANDRA/IMpassion030 phase 3 trial found that adding atezolizumab to chemotherapy after surgery did not improve survival for early-stage triple-negative breast cancer patients. Researchers also found no benefit in different sub-groups, such as those with lymph node spread and PD-L1 positive cancer.
A new genetic test has identified patients with triple negative early-stage breast cancer who are unlikely to respond to immunotherapy drugs. The test, called ImPrintTN, can predict a patient's likelihood of responding to these treatments and help avoid severe side effects.
A study by IRB Barcelona and Sant Joan de Déu Hospital reveals three distinct patterns explaining the occurrence of second cancers in children, including a mutational footprint from chemotherapy. The research advances understanding of pediatric cancer and highlights the importance of clinical data sharing.
New data show that adding pembrolizumab to chemotherapy before and after surgery for breast cancer leads to better outcomes, with significant increases in pathological complete response rates across all age groups. The study also found similar rates of breast-conserving surgery and mastectomy, as well as lower residual cancer burdens.
A research team at the University of Cologne has identified mechanisms governing drug response in small cell lung cancer. The study reveals that large populations of treatment-sensitive cells often hide numerous therapy-resistant cells that can multiply unchecked after successful treatment.
Researchers have deciphered trabectedin's precise mechanism of action, revealing its ability to induce persistent DNA breaks in cancer cells. This disruption of the transcription-coupled nucleotide excision repair (TC-NER) pathway leads to long-lasting DNA breaks that ultimately kill cancer cells.
Researchers at MIT discovered that daily exposure to light and sound with a frequency of 40 hertz protects brain cells from chemotherapy-induced damage, preventing memory loss and improving cognitive functions. The treatment also helped prevent DNA damage, inflammation, and promoted the growth of oligodendrocytes, the cells responsible...
A new study reveals that MAGE family proteins bind to RAD18 using a groove, preventing its degradation and contributing to cancer progression. The findings also suggest that blocking this interaction could lead to re-sensitization of cancer cells to chemotherapy and radiotherapy.
Researchers investigated combining Sacituzumab govitecan with platinum-based chemotherapeutics for triple-negative breast cancer, urinary bladder carcinoma, and small-cell lung carcinoma. The study showed additive to synergistic antitumor effects in vitro and in vivo, with improved outcomes in tumor-bearing animals.
The European LeukemiaNet has published two-part guidelines for adult acute lymphoblastic leukemia treatment, covering diagnostics, prognostic factors, response assessments, and comprehensive management. These recommendations are based on a decade of systematic work by European experts, improving the prognosis of adult patients with ALL.
Researchers developed an oxidative stress-based prognostic model for bladder cancer, identifying distinct molecular subtypes and predicting patient outcomes. The model shows promise in tailoring personalized treatment approaches, particularly for patients with low-risk profiles.
Head and neck cancer patients exposed to secondhand smoke during chemotherapy have reduced treatment effectiveness. Secondhand smoke alters protein expression, restricting chemotherapy's ability to kill cancer cells. This raises concerns about cancer prognosis and the importance of smoking cessation.
Two new studies reveal that UK cancer patients face long waits for chemotherapy and radiotherapy, leading to poorer outcomes. The research highlights the need for a strategic approach to addressing treatment variation and improving cancer services in the UK.
Researchers created Elenagen, a novel DNA immunotherapy for deadly ovarian cancer, which significantly enhances standard chemotherapy and provides clinical benefits. The study shows that Elenagen delays disease progression in patients with stage III and IV platinum-resistant ovarian cancer.
Researchers have discovered a new way to target chemotherapy-resistant ovarian cancer cells by depriving them of cholesterol, leading to significant tumor growth reduction. The nanoparticles starve the cells of cholesterol, triggering cell death through oxidation of lipids in the cell membrane.
Research shows that lowering doses and adjusting chemotherapy schedules for older adults with advanced cancer can reduce toxic side effects and preserve daily functions. Over 30% of patients benefited from treatment regimen modifications, with a 15% reduced risk of serious clinician-rated toxic effects.
A large retrospective cohort analysis found that neoadjuvant chemotherapy improved overall and progression-free survival for locally advanced penile squamous cell carcinoma patients. The study also showed that platinum-based chemotherapy was well-tolerated, with low treatment-related mortality.
A new treatment combining a novel drug with traditional chemotherapy has been shown to increase the survival of patients with malignant mesothelioma, a rare and aggressive cancer. The ATOMIC-meso trial found that this treatment quadrupled the survival at 36 months compared to placebo-chemotherapy.
A four-drug chemotherapy regimen, NALIRIFOX, has been approved by the FDA for frontline treatment of metastatic pancreatic adenocarcinoma. The regimen, combining irinotecan liposome, oxaliplatin, leucovorin, and fluorouracil, resulted in longer overall survival compared to a two-drug protocol.
Researchers discovered genes encoding growth regulators normally not present in myeloid cells are expressed by leukaemic stem cells, allowing them to grow. Repurposed drugs targeting these receptors show promise in blocking stem cell growth and preventing disease relapse in specific types of AML.
Researchers found that USP1 inhibits cdc42, increases EWS-FLI1 transcriptional output, and simulates Ewing sarcoma growth. A pharmacological inhibitor of USP1 activated cdc42 and inhibited Ewing sarcoma growth.
A team of physicists and veterinary scientists at Purdue University has developed a method to detect chemoresistance in cancer patients using biodynamic imaging (BDI). This technique measures the motions inside cancer cells and how they respond to chemotherapy, identifying patients who will not respond to treatment. The study shows pro...
Researchers propose a novel augmentation regimen, IPIAD, combining five generic non-oncology drugs with standard chemotherapy for pancreatic ductal adenocarcinoma. The IPIAD regimen uses repurposed drugs like irbesartan and azithromycin to potentially slow disease growth and improve outcomes.
Researchers identified mechanisms that cause ponatinib to harm the heart and found a promising treatment that could reverse this process. The treatment protects heart cells without diminishing the tumor-fighting efficacy of the drug.
Researchers discovered a link between single cancer cell mutations and clinical response to epigenetic therapy in myelodysplastic syndrome. Patients showing treatment benefits had decreased mutation counts in stem cells and immature granulocytes, suggesting early tumor elimination is key to therapy success.
A team of researchers found that diffuse anaplasia (DA) subtype of Wilms tumor grows despite high DNA damage and TP53 mutation, leading to resistance to chemotherapy. The study suggests that DA histology emerges through accumulating DNA damage and CNAs, creating selection pressure for TP53 mutations.
A team led by UCF College of Nursing Professor Victoria Loerzel developed an innovative educational game for older adults with cancer, simulating symptoms and self-management. The game was successful in increasing the use of preventative strategies among participants, reducing symptom severity and hospital admissions.
A study found that the 21-gene breast recurrence score test may underestimate chemotherapy benefits for young Black women with estrogen receptor-positive breast cancer. The researchers recommend lowering the test's cutoff point to ensure accurate treatment recommendations for all patients regardless of race or ethnicity.
Researchers discovered that cisplatin chemotherapy enhances the immune system's ability to fight bladder cancer by modulating the immune response and damaging DNA in cancer cells. This approach may lead to durable disease control in a subset of patients with metastatic bladder cancer.
Researchers found that high levels of FSP1 are associated with relapse after cisplatin treatment in head and neck squamous cell carcinoma. Targeting FSP1 can attenuate tumor stemness and downregulate invasion and metastatic rates, suggesting a potential new approach for treating drug-tolerant persister cancer cells.
Senescent tumour cells generated by chemotherapy can create an environment that helps tumour cells escape treatment. Eliminating these cells with immunotherapy boosts the effectiveness of chemotherapy.
Researchers at Washington State University have discovered a key protein in prostate cancer cells' resistance to docetaxel. Blocking this protein, CHRM1, with dicyclomine restored the effectiveness of docetaxel and reduced tumor growth.